|
Protein
Nanoparticles
Aphios
Corporation’s protein nanoparticles technology platform
utilizes the expansive energy of SuperFluids™
to disaggregate or comminute protein crystals and amorphous
powders into monodisperse nanoparticles [U.S. Patent No. 6,051,694,
April 18, 2000]. SuperFluids™ encompass gases such as
carbon dioxide which, when compressed, exhibit enhanced thermodynamic
properties of solvation, selection and expansion.
Impact
of Pressure: In the example shown for bovine serum
albumin (BSA), protein size reduction increases non-linearly
with pressure, approaching an asymptote between 3,000 and
4,000 psig for carbon dioxide. This trend is supported by
the mechanism that higher pressures will result in higher
expansive forces. The data indicates that extremely high pressures
are not required for efficient protein comminution utilizing
this technology.
Impact of Protein Type: The optimal conditions
established for the SuperFluids™ comminution of insulin
were utilized to evaluate the impact of protein type. This
evaluation, shown in the adjacent table, indicates that the
process is extremely robust for a wide range of proteins,
molecular weights and particle sizes. Some fine-tuning may
be required for specific proteins.
Impact
on Bioactivity: As shown for insulin, the protein
nanoparticles retain full activity after processing. For certain
proteins, biological activity is enhanced because active sites
are more exposed after comminution.
Aphios’ patented SuperFluids™ PNP (protein nanoparticle)
process forms monodisperse protein particles without having
to first dissolve the protein in a liquid solvent. The process
is thus not constrained by limited solubility in benign solvents
such as ethanol that may be used with other supercritical
fluid techniques, and the utilization of large volumes of
liquids that limits other techniques such as spray drying.
The process also produces a Joule-Thompson cooling effect,
and thus avoids heat associated with milling techniques that
can cause protein degradation and contamination by metal particles.
The SuperFluids™ PNP process is simple and
scalable.
Home
l Company | Infectious
Diseases | Oncology | Nutraceuticals
| Product Pipeline | Purchase
Products | Technology Platforms
| Equipment |Patents
| Press
Releases | Contact Aphios
©1999-
2007 Aphios® Corporation
All rights reserved
|